LOS ANGELES, CA / ACCESSWIRE / July 20, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Roche Holding AG ("Roche" or the "Company") (OTCQX: RHHBY) for possible violations of federal securities laws from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired Roche shares during the Class Period, should contact the firm prior to the August 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet, and until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that throughout the Class Period, Roche issued materially false and misleading statements, and/or failed to disclose, that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more successful than Herceptin alone in preventing breast cancer; and that as a result, Roche's statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. Following this news, Roche's stock price decreased materially, causing investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
SOURCE: Lundin Law PC
